Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?

Bibliography

• BENNETT JM, CATOVSKY D, DANIEL MT et al: Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. (1985) 103:620–625.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory comittee meeting - Airlie House, Virginia, November 1997. j Clin arca (1999) 17:3835–3849.
   PubMed Web of Science ®Google Scholar
• MAYER RJ, DAVIS RB, SCHIFFER CA et al.: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl. Med. (1994) 331:896–903.
   PubMed Web of Science ®Google Scholar
• ••The large randomised study that firstdescribed improved long-term AML-free survival of patients treated with high-dose cytarabine.
   Google Scholar
• BISHOP JF, MATTHEWS JP, YOUNG GA et al.: A randomized study of high-dose cytarabin in induction in acute myeloid leukemia. Blood (1996) 87:1710–1717.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL: Acute myeloid leukemia in the elderly. Blood Rev (1998) 12:145–153.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W KERN W SCHOCH C et al.: Management of acute myeloid leukemia in elderly patients. j Clin arca (1999) 17:3569–3576.
   Web of Science ®Google Scholar
• ZITTOUN RA, MANDELLI F, WILLEMZE R et al.: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl. Med. (1995) 332:217–223.
   PubMed Web of Science ®Google Scholar
• CASSILETH PA, HARRINGTON DP, APPELBAUM FR etal.: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl. j Med. (1998) 339:1649–1656.
   Google Scholar
• MICHALLET M, THOMAS X, VERNANT JP et al.: Longterm outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplani (2000) 26:1157–1163.
   PubMed Web of Science ®Google Scholar
• LOWENBERG B, DOWNING JR, BURNETT A: Acute myeloid leukemia. N Engl. J. Med. (1999) 341:1051–1062.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0: Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia (1999) 13:1175–1187.
   PubMed Web of Science ®Google Scholar
• SCHWARER AE JIANG YZ, BROOKES PA et al: Frequency of anti-recipient alloreactive helper T cell precursors in donor blood and graft versus host disease after HLA-identical sibling bone marrow transplantation. Lancet (1993) 341:203–205.
   PubMed Web of Science ®Google Scholar
• NIEDERWIESER D, GRASSEGGER A, AUBOCK J et al: Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft versus host disease status and analysis of tissue distribution of their target antigens. Blood (1993) 81:2200–2208.
   PubMed Web of Science ®Google Scholar
• VOGELSANG GB, MORRIS LE: Prevention and management of graft versus host disease. Practical recommendations. Drugs (1993) 45:668–676.
   Google Scholar
• FERRARA JLM, DEEG HJ: Graft versus host disease. N Engl. J. Med. (1991) 324:667–674.
   PubMed Web of Science ®Google Scholar
• SIADAK M, SULLIVAN KM: The management of chronic graft versus host disease. Blood Rev (1994) 8:154–160.
   PubMed Web of Science ®Google Scholar
• GALE RE HOROWITZ MM, ASH RC et al.: Identical-twin bone marrow transplants for leukemia. Ann. Intern. Med. (1994) 120:646–652.
   PubMed Web of Science ®Google Scholar
• COLLINS RH, SHPILBERG 0, DROBYSKI WR et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. j Clin. arca (1997) 15:433–444.
   PubMed Web of Science ®Google Scholar
• •A large clinical study describing the results for treatment of post-transplant leukaemia relapse with infusion of donor leukocytes.
   Google Scholar
• KOLB HJ, SCHATTENBERG A, GOLDMAN JM et al: Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 86:2041–2050.
   PubMed Web of Science ®Google Scholar
• •The first large clinical study describing the effect of donor leukocyte infusions in the treatment of leukaemia relapse after allotransplantation.
   Google Scholar
• PORTER DL, ROTH MS, LEE SJ, McGARIGLE C, FERRARA JLM, ANTIN JH: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. (1996) 18:975–980.
   PubMed Web of Science ®Google Scholar
• GOODMAN M, CABRAL L, CASSILETH P: Interleukin 2 and leukemia. Leukemia (1998) 12: 1671-1675.
   Google Scholar
• MELONI G, VIGNETTI M, POGLIANI E et al: Interleukin 2 therapy in relapsed acute myelogenous leukemia. Cancer j Sri. Am. (1997) 3: (Supp1.1):S43–S47.
   Google Scholar
• ••The clinical experiences with IL-2 therapyin a large group of AML patients is reported.
   Google Scholar
• BOUGHTON BJ, SIMPSON AW: Acute myeloblastic leukemia: graft versus host and graft versus leukemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease. Cytokines Cell Mal Ther. (1999) 5:1–6.
   PubMedGoogle Scholar
• MARANINCHI D, VEY N, VIENS P etal.: A Phase II study of interleukin 2 in 49 patients with relapsed and refractory acute leukemia. Leuk. Lymphoma (1998) 31:343–349.
   Google Scholar
• BERGMANN L, HEIL G, KOLBE K et al: Interleukin 2 bolus infusion as late consolidation therapy in 2'd remission of acute myeloblastic leukemia. Leuk. Lymphoma (1995) 16:271–279.
   PubMed Web of Science ®Google Scholar
• MASSUMOTO C, BENYUNES MC, SALE G et al.: Close simulation of acute graft versus host disease by interleukin 2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant. (1996) 17:351–356.
   PubMed Web of Science ®Google Scholar
• BLAISE D, ATTAL M, REIFFERS J etal.: Randomized study of recombinant interleukin 2 after autologous bone mauuw transplantation for acute leukemia in first remission. ELIE Cytokine Netw (2000) 11:91–98.
   Google Scholar
• MELONI G, FOA R, VIGNETTI M et al: Interleukin 2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood (1994) 84:2158–2163.
   PubMed Web of Science ®Google Scholar
• •The first report of AML remission induction after IL-2 therapy.
   Google Scholar
• SIEVERS EL, LANGE BJ, SONDEL PM et al.: Children's cancer group trial of interleukin 2 therapy to prevent relapse of acute myelogenous leukemia. Cancer Am. (2000) 6\(Suppl. 1):S39–S44.
   Google Scholar
• GANSER A, HEIL G, SEIPELT G et al: Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin 2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann. Haematol (2000) 79:30–35.
   PubMed Web of Science ®Google Scholar
• CORTES JE, KANTARJIAN HM, O'BRIEN S et al: A pilot study of interleukin 2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer (1999) 85:1506–1513.
   PubMed Web of Science ®Google Scholar
• MESSINA C, ZAMBELLO R, ROSSETTI F et al.: Interleukin 2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients. Bone Marrow Transplant (1996) 17:729–735.
   PubMed Web of Science ®Google Scholar
• SCHULTZE J, NADLER LM, GRIBBEN JG: B7-mediated costimulation and the immune response. Blood Rev (1996) 10:111–127.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, ULVESTAD E: Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immurrol (2000) 206:36–50.
   PubMed Web of Science ®Google Scholar
• •This study characterises the co-stimulatory pathways for native AML blasts derived from a group of AML patients.
   Google Scholar
• BROUWER RE, ZWINDERMAN KH, KLUIN-NELEMANS HC et al: Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp. Hematol. (2000) 28:161–168.
   PubMed Web of Science ®Google Scholar
• •Characterisation of the various T-cell co-stimulatory pathways in AML blasts.
   Google Scholar
• COSTELLO RT, MALLET E SAINTY D, MARANINCHI D, GASTAUT JA, OLIVE D: Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogeneic immune recognition. Eur. Immurrol (1998) 28:90–103.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, ULVESTAD E: Effects of 7-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation. j Hematother. Stem Cell Res. (1999) 8:431–441.
   PubMedGoogle Scholar
• HIRANO N, TAKAHASHI T, TAKAHASHI T et al: Expression of costimulatory molecules in human leukemias. Leukemia (1996) 10:1168–1176.
   PubMed Web of Science ®Google Scholar
• •Characterisation of the expression of HLA molecules and various T-cell co-stimulatory molecules in native AML blasts derived from a large group of patients.
   Google Scholar
• HARRIS PE, MAFFEI A, COLOVAI Al et al.: Predominant HLA-class II bound self peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Blood (1996) 87:5104–5112.
   PubMed Web of Science ®Google Scholar
• CASASNOVAS RO, CAMPOS L, MUGNERET F et al: Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. Leukemia (1998) 12:34–43.
   PubMed Web of Science ®Google Scholar
• TEN BOSCH GJA, JOOSTEN AML, KESSLER JH etal.: Recognition of bcr-abl positive leukemia blasts by human CD4+ T cells elicited by primary in vitro immunization with a bcr-abl breakpoint peptide. Blood (1996) 88:3522–3527.
   Google Scholar
• GAMBACORTI-PASSERINI C, GRIGNANI F, ARIENTI F et al: Human CD4 T lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARa present in acute promyelocytic leukemic cells. Blood (1993) 81:1369–1375.
   PubMed Web of Science ®Google Scholar
• PAWELEC G, MAX H, HALDER T etal.: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood (1996) 88:2118–2124.
   Google Scholar
• YASUKAWA M, OHMINAMI H, KANEKO S etal.: CD4+ cytotoxic T cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR restricted manner. Blood (1998) 92:3355–3361.
   Google Scholar
• ••The study described that activation ofleukaemia-reactive cytotoxic T-cell clones can result in increased leukaemia cell proliferation possibly due to T-cell cytokine release.
   Google Scholar
• MAEDA M, OTSUKA T, KIMURA N, et al.: Induction of MTG8-specific cytotoxic T cell lines: MTG8 is probably a tumor antigen that is recognized by cytotoxic T cells in AML1-MTG8-fused gene-positive acute myelogenous leukaemia. Br Haematol (2000) 111:570–579.
   Google Scholar
• BRUGGER W, BÜHRING HJ, GRONEBACH F etal.: Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. j Chu. Oricol. (1999) 17:1535–1544.
   Google Scholar
• BROSSART P, SCHNEIDER A, DILL Pet al.: The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T cells. Cancer Res. (2001) 61:6846–6850.
   Google Scholar
• MOLLDREM J, DERMINE S, PARKER K etal.: Targeted T cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from protease 3 preferentially lyse human myeloid leukemia cells. Blood(1996) 88:2450–2457.
   Google Scholar
• FU GK, GROSVELD G, MARKOVITZ DM: DEK, an autoantigen involved in a chromosome translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. Proc. Natl. Acad. Sci. USA (1997) 94:1811–1815.
   PubMed Web of Science ®Google Scholar
• GLUCKMAN JC, CANQUE B, CHAPUIS F, ROSENZWAJG M: In vitro generation of human dendritic cells and cell therapy. Cytokirres Cell Mol. Ther. (1997) 3:187–196.
   PubMedGoogle Scholar
• SRIVASTAVA BI, SRIVASTAVA A, SRIVASTAVA MD: Phenotype, genotype and cytokine production in acute leukemia involving progenitors of dendritic Langerhans cells. Leuk. Res. (1994) 18:499–511.
   PubMed Web of Science ®Google Scholar
• CHOUDHURY BA, LIANG JC, THOMAS EK et al: Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T cell responses. Blood (1999) 93:780–786.
   PubMed Web of Science ®Google Scholar
• ••AML blasts with a dendritic cell phenotypecan enhance autologous T-cell reactivity against native AML cells.
   Google Scholar
• CIGNETTI A, BRYANT E, ALLIONE B et al.: CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood (1999) 94:2048–2055.
   PubMed Web of Science ®Google Scholar
• CHARBONNIER A, GAUGLER B, SAINTY D et al: Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur. Immurrol. (1999) 29:2567–2578.
   PubMed Web of Science ®Google Scholar
• ••AML blasts with a dendritic cell phenotypecan enhance autologous T-cell reactivity against native AML cells.
   Google Scholar
• SANTIAGO-SCHWARZ F, COPPOCK DL, HINDENBURG AA, KERN J: Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in acute myeloid leukemia. Blood (1994) 84:3054–3062.
   PubMed Web of Science ®Google Scholar
• PANOSKALTSIS N, BELANGER T, ROSELL K et al: Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells: a novel strategy for adoptive immunotherapy of leukemia. Blood (1998) (Suppl. 1):618a.
   Google Scholar
• LIU Z, SUN YK, XI YP etal.: Contributionof direct and indirect recognition pathways 1014 to T cell alloreactivity. j Exp. Med. (1993) 177:1643–1650.
   Google Scholar
• REID DC: Dendritic cells and immunotherapy for malignant diseases. Br Haematol. (2001) 112:874–887.
   PubMed Web of Science ®Google Scholar
• VAN TENDELOO VF, VAN BROECKHOVEN C, BERNEMAN ZN: Gene-based cancer vaccines: an ex vivo approach. Leukemia (2001) 15:545–558.
   PubMed Web of Science ®Google Scholar
• BONNET D, WARREN EH, GREENBERG PD, DICK JE, RIDDELL SR: CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sd. USA (1999) 96:8639–8644.
   PubMed Web of Science ®Google Scholar
• ••Antigen-specific cytotoxic T-cells eliminateAML engraftment in immunocompromised mice.
   Google Scholar
• BRUSERUD 0, ULVESTAD E, BERENTSEN S, BERGHEIM J, NESTHUS I: T lymphocyte functions in acute leukemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T cell proliferation. Scand. j brotturioL (1998) 47:54–62.
   Google Scholar
• BRUSERUD 0, HAMANN W, PATEL S, EHNINGER G, SCHMIDT H, PAWELEC G: IFN-y and TNF-a secretion by CD4+ and CD8+ TCRalk T cell clones derived early after allogeneic bone marrow transplantation. Eur. j HaematoL (1993) 51:73–79.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, EHNINGER G, HAMANN W, PAWELEC G: Secretion of IL2, IL3, IL4, IL6 and GM-CSF by CD4+ and CD8+ TCRalk T cell clones derived early after allogeneic bone marrow transplantation. Scarid. j brimurioL (1993) 38:65–74.
   Google Scholar
• BRUSERUD 0: Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic cells. Cancer ImmurioL Immuriother. (1998) 46:221–228.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, FOSS B, PETERSEN H: Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin 3 (IL3) and F1t3-Ligand (F1t3-L). Eur. Cytokine Netw (2001) 12:231–238.
   PubMed Web of Science ®Google Scholar
• MACKALL CL, FLEISCHER TA, BROWN MR et al.: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood (1994) 84:2221–2228.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, ULVESTAD E, HALSTENSEN A, BERENTSEN S, BERGHEIM J, NESTHUS I: Interleukin 4 responses in acute leukemia patients with severe chemotherapy-induced leucopenia. Eur. j HaematoL (1997) 59:269–276.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, VON VOLKMAN HL, ULVESTAD E: The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL16 and IL17. Acta HaematoL (2000) 104:80–91.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, ULVESTAD E: Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia. Interferon Cytokine Res. (2000) 20:947–954.
   PubMed Web of Science ®Google Scholar
• ••The cytokine responsiveness of circulatingT-cells derived from acute leukaemia patients with chemotherapy-induced leukopenia is characterised.
   Google Scholar
• NAMIKAWA R, WEILBAECHER KN, KANESHIMA H, YEE EJ, MCCUNE JM: Long-term human hematopoiesis in the SCID-hu mouse. j Exp. Med. (1990) 172:1055–1063.
   PubMed Web of Science ®Google Scholar
• PEAULT B, WEISSMAN IL, BAUM C, MCCUNE JM, TSUKAMOTO A: Lymphoid reconstitution of the fetal thymus in SCID-hu mice with CD34+ precursor cells. j Exp. Med. (1991) 174:1283–1286.
   PubMed Web of Science ®Google Scholar
• DIGIUSTO D, CHEN S, COMBS J etal.: Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34. Blood (1994) 84:421–432.
   Google Scholar
• DE LA HERA A, MARSTON W ARANDA C, TORIBIO ML, MARTINEZ C: Thymic stroma is required for the development of human T cell lineage in vitro. Int. brimurioL (1989) 1:471–478.
   Google Scholar
• ESHEL I, SAVION N, SHOHAM J: Analysis of thymic stroma cell subpopulation growth in vitro on extracellular matrix in defined medium. II. Cytokine activities in murine thymic epithelial and mesenchymal cell culture supernatants. j ImmurioL (1990) 144:1563–1570.
   Google Scholar
• LE PT, TUCK DT, DINARELLO CA, HAYNES BE SINGER KH: Human thymic epithelial cells produce interleukin if f brimurioL (1987) 138:2520–2526.
   Google Scholar
• FRIEND SL, HOSIER S, NELSON A, FOXWORTHE D, WILLIAMS DE, FARR A: A thymic stroma cell line supports in vitro development of surface IgM+ B cells and produce a novel growth factor affecting B and T lineage cells. Exp. HematoL (1994) 22:321–328.
   PubMed Web of Science ®Google Scholar
• OOSTERWEGEL MA, HAKS MC, JEFFRY U, MURRAY R, KRUISBEEK AM: Induction of TCR gene rearrangements in uncommitted stem cells by a subset of IL7-producing, MHC class II-expressing thymic stromal cells. Immunity (1997) 6:351–360.
   PubMed Web of Science ®Google Scholar
• BOLOTIN E, SMOGORZEWSKA M, SMITH S, WIDMER M, WEINBERG K: Enhancement of thymopoiesis after bone marrow transplant by in vitro interleukin 7. Blood(1996) 88: 1887-1894.
   Google Scholar
• PLUM J, De SMEDT M, DEFRESNE MP, LECLERCQ G, VANDEKERCKHOVE B: Human CD34+ fetal liver stem cells differentiate to T cells in a mouse thymic microenvironment. Blood (1994) 84:1587–1593.
   PubMed Web of Science ®Google Scholar
• MACKALL CL, FRY TJ, BARE C, MORGAN E GALBRAITH A, GRESS RE: IL7 increases both thymic-dependent and thymic-independent T cell regeneration after bone marrow transplantation. Blood (2001) 97:1491–1497.
   PubMed Web of Science ®Google Scholar
• FRY TJ, CHRISTENSEN BL, KOMSCHLIES KL, GRESS RE, MACKALL CL: Interleukin 7 restores immunity in athymic T cell depleted hosts. Blood(2001) 97:1525–1533.
   PubMed Web of Science ®Google Scholar
• FRY TJ, CONNICK E, FALLOON J etal.: A potential role of interleukin 7 in T cell homeostasis. Blood (2001) 97:2983–2990.
   Google Scholar
• •This article described the possible role of IL-7 in T-cell homeostasis in patients with HIV-infections and chemotherapy-induced T-lymphopenia.
   Google Scholar
• DECASTRO CM, DENNING SM, LANGDON S et al.: The c-kit proto-oncogene receptor is expressed on a subset of human CD3-CD4-CD8- (triple-negative) thymocytes. Erp. HematoL (1994) 22:1025–1033.
   Google Scholar
• FOSS B, NESTHUS I, BERGHEIM J, BRUSERUD 0: Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating bacterial infections. Platelets (1999) 10:17–23.
   PubMed Web of Science ®Google Scholar
• MACKALL CL, FLEISCHER TA, BROWN MR et al.: Age, thymopoiesis and CD4+ T lymphocyte regeneration after intensive chemotherapy. N Engl. j Med. (1995) 332:143–149.
   PubMed Web of Science ®Google Scholar
• •One of the first articles characterising the long-lasting CD4+ defect in patients receiving intensive chemotherapy for malignant disorders.
   Google Scholar
• MACKALL CL, FLEISCHER TA, BROWN MR et al: Distinctions between CD8+ and CD4+ T cell regenerative pathways result in prolonged T cell subset imbalance after intensive chemotherapy. Blood (1997) 89:3700–3707.
   PubMed Web of Science ®Google Scholar
• ALTIN JG, SLOAN EK: The role of CD45 and CD45-associated molecules in T cell activation. Immurrol Cell Biol. (1997) 75:430–445.
   PubMed Web of Science ®Google Scholar
• CHOYKE PL, ZEMAN RK, GOOTENBERG JE, GREENBERG JN, HOFFER E FRANK JA: Thymic atrophy and regrowth in response to chemotherapy: CT evaluation. Am. j Roentgerrol (1987) 149:269–272.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, TJONNFJORD G, GJERTSEN BT, FOSS B, ERNST P: New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients. Stem Cells (2000) 18:-343–351.
   Google Scholar
• •This is an updated review of the experience with autologous SCT in AML.
   Google Scholar
• BURNETT AK, GOLDSTONE AH, STEVENS RMF et al: Randomised comparison of addition of autologous transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. Lancet (1998) 351:700–708.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL, CAHN JY, PIGNON B et al: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood (1997) 90:2978–2986.
   PubMed Web of Science ®Google Scholar
• VISANI G, LEMOLI RIVI, TOSI P et al:Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia allows faster engraftment and equivalent disease-free survival compared with bone marrow. Bone Marrow Transplant (1999) 24:467–472.
   PubMed Web of Science ®Google Scholar
• LOWENBERG B, Van PUTTEN WLJ, FERRANT A etal.: Peripheral blood progenitor transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Stem Cells (1997) 15\(Suppl. 0:177–180.
   Google Scholar
• DE LA RUBIA J, SANZ MA: Autologous peripheral blood stem cell transplantation for acute leukemias. Bailliere's Best Pict. Res. Chu. Haematol (1999) 12:139–150.
   PubMed Web of Science ®Google Scholar
• BRUSERUD 0, FOSS B, ABRAHAMSEN GJERTSEN BT, ERNST P: Autologous stem cell transplantation as postremission therapy in adult patients with acute myelogenous leukemia: does platelet contamination of peripheral blood stem cell grafts influence the risk of leukemia relapse? Hematother. Stem Cell Res. (2000) 9:433–443.
   Web of Science ®Google Scholar
• FOSS B, ABRAHAMSEN JF, BRUSERUD 0: Peripheral blood stem cell grafts contain high levels of platelet-secreted mediators. Transfusion (2001). In press.
   Google Scholar
• VARNEY ML, INO K, AGEITOS AG et al.: Expression of interleukin 10 in isolated CD8+ T cells and monocytes from growth factor-mobilized peripheral blood stem cell products: a mechanism of immune dysfunction. I Interferon Cytokine Res. (1999) 19:351–360.
   PubMed Web of Science ®Google Scholar
• SINGH RK, INO K, VARNEY ML, HEIMANN DG, TALMADGE JE: Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Bone Marrow Transplant (1999) 23:53–62.
   PubMed Web of Science ®Google Scholar
• INO K, SINGH RK, TALMADGE JE: Monocytes from mobilized stem cells inhibit T cell function. j Leukoc. Biol. (1997) 61:583–591.
   PubMed Web of Science ®Google Scholar
• TANAKA J, MIELCAREK M, TOROK-STORB B: Impaired induction of the CD28-responsive pathway in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood (1998) 91:347–352.
   PubMed Web of Science ®Google Scholar
• TALMADGE JE, REED E, INO K et al: Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant (1997) 19:161–172.
   PubMed Web of Science ®Google Scholar
• HENON PR, LIANG H, BECK-WIRTH G et al: Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant (1992) 9:285–291.
   PubMed Web of Science ®Google Scholar
• GALY A, RUDRARAJU S, BAYNES R, KLEIN J: Recovery of lymphocytes and dendritic cell subsets after autologous CD34+ cell transplantation. Bone Marrow Transplant (2000) 25:1249–1255.
   PubMed Web of Science ®Google Scholar
• TALMADGE JE, REED EC, KESSINGER A et al: Immunologic attributes to cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant (1996) 17:101–109.
   PubMed Web of Science ®Google Scholar
• DREGER P, VIEHMANN K, VON NEUHOFF N et al: Autografting of highly purified blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant (1999) 24:153–161.
   PubMed Web of Science ®Google Scholar
• MACKALL CL, STEIN D, FLEISCHER TA et al.: Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood (2000) 96:754–762.
   PubMed Web of Science ®Google Scholar
• ••The article gives a detailed characterisationof T-cell recovery after autologous SCT. High age was identified as the most important predictor for late CD4+ recovery.
   Google Scholar
• SINGH RK, VARNEY ML, BUYUKBERBER S etal.: Fas-FasL-mediated CD4+ T cell apoptosis following stem cell transplantation. Cancer Res. (1999) 59:3107–3111.
   Google Scholar
• FUJII SI, FUJIMOTO K, SHIMIZU K et al.: Presentation of tumor antigens by dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: Induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia. Cancer Res. (1999):2150–2158.
   PubMed Web of Science ®Google Scholar
• OSTANKOVITCH M, BUZYN A, BONHOMME D et al: Antileukemic HLA-restricted T cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts. Blood (1998) 92:19–24.
   PubMed Web of Science ®Google Scholar